Global Veterinary Vaccines Market: By Product Type (Live Stock Vaccines (Bovine Vaccine, Poultry Vaccines, and Small Ruminants Vaccine), Companion Animal Vaccine (Canine Vaccines and Feline Vaccines), Porcine Vaccines, Equine Vaccines, and Others), By Disease Type (Live Stock Diseases (Foot and Mouth Disease, Brucellosis, Infectious Bronchitis, Marek’s Disease, Newcastle Disease, and Others), Companion Animal Diseases (Canine Distemper, Canine Parvovirus, Feline Rabies and Others) Equine Diseases, Porcine Diseases, and Aquaculture Diseases), By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Recombinant vaccines, Toxoid vaccines, Conjugate Vaccines, DNA Vaccines, and Subunit Vaccines), Distribution Channel (Veterinary Pharmacies, Veterinary Hospitals, Veterinary Clinics, and E-Commerce), and Geography - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Global Veterinary Vaccines Market Report Description:
Veterinary Vaccines market report gives comprehensive outlook on veterinary vaccines market across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on veterinary vaccines market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, disease type, vaccine type, distribution channel, and geographic regions. This report studies veterinary vaccines market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, veterinary vaccines market report includes animal demographics; regulatory scenario, top meat producing countries, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed veterinary vaccines market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the veterinary vaccines market report include suppliers, manufacturers, marketers, policy makers, and veterinary healthcare service providers engaged in manufacturing and supply of veterinary vaccines products.
Global Veterinary Vaccines Market:
The veterinary vaccines market estimated to be valued US$ 6,029 Mn in 2017 and poised to grow at CAGR of 5.6% over 2017-2023. Market for veterinary vaccines projected to reach US$ 8,368 Mn by 2023 owing to rising immunization programs in animals and increasing stakeholder involvement to contain disease in animals.
Rising meat and animal trade restrictions expected to drive the veterinary vaccine market over the forecast period
The rise in demand for safe and effective meat for consumption and rising trade restriction of meat and animal owing to zoonotic diseases expected to create demand for veterinary vaccines over the forecast period. For instance, Global Rinderpest Eradication Program aims at vaccination, trade restrictions, and surveillance of rinderpest in animals. Moreover, market growth is driven by improving food security and rising human and pet bondage adoption in recent times.
Constrained resources impeding the market revenue growth
Growth of veterinary vaccines Market expected to hinder over forecast period owing to lack of cold chain infrastructure for vaccine storage and transportation in several developing and underdeveloped economies. Moreover, dearth of diseases surveillance data for carving out effective immunization programs expected to impede veterinary vaccine market growth over the forecast period.
Europe accounted for larger market revenue share in global veterinary vaccines market
Europe accounted for larger revenue share in global veterinary vaccines market with moderate CAGR. There has been increase in awareness among cattlemen in U.S. regarding animal rearing, animal health and proper vaccination and judicious use of antibiotics in animals, which are driving the market revenue growth in the region. Asia pacific market projected to grow at significant rate owing large pool of animal population and increased consumption and trade of meat.
COMPETITION ASSESSMENT
Key players profiles in the global veterinary vaccines market include:
KEY FINDINGS OF THE REPORT:
By Product Type
Veterinary Vaccines market report gives comprehensive outlook on veterinary vaccines market across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on veterinary vaccines market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, disease type, vaccine type, distribution channel, and geographic regions. This report studies veterinary vaccines market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, veterinary vaccines market report includes animal demographics; regulatory scenario, top meat producing countries, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed veterinary vaccines market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the veterinary vaccines market report include suppliers, manufacturers, marketers, policy makers, and veterinary healthcare service providers engaged in manufacturing and supply of veterinary vaccines products.
Global Veterinary Vaccines Market:
The veterinary vaccines market estimated to be valued US$ 6,029 Mn in 2017 and poised to grow at CAGR of 5.6% over 2017-2023. Market for veterinary vaccines projected to reach US$ 8,368 Mn by 2023 owing to rising immunization programs in animals and increasing stakeholder involvement to contain disease in animals.
Rising meat and animal trade restrictions expected to drive the veterinary vaccine market over the forecast period
The rise in demand for safe and effective meat for consumption and rising trade restriction of meat and animal owing to zoonotic diseases expected to create demand for veterinary vaccines over the forecast period. For instance, Global Rinderpest Eradication Program aims at vaccination, trade restrictions, and surveillance of rinderpest in animals. Moreover, market growth is driven by improving food security and rising human and pet bondage adoption in recent times.
Constrained resources impeding the market revenue growth
Growth of veterinary vaccines Market expected to hinder over forecast period owing to lack of cold chain infrastructure for vaccine storage and transportation in several developing and underdeveloped economies. Moreover, dearth of diseases surveillance data for carving out effective immunization programs expected to impede veterinary vaccine market growth over the forecast period.
Europe accounted for larger market revenue share in global veterinary vaccines market
Europe accounted for larger revenue share in global veterinary vaccines market with moderate CAGR. There has been increase in awareness among cattlemen in U.S. regarding animal rearing, animal health and proper vaccination and judicious use of antibiotics in animals, which are driving the market revenue growth in the region. Asia pacific market projected to grow at significant rate owing large pool of animal population and increased consumption and trade of meat.
COMPETITION ASSESSMENT
Key players profiles in the global veterinary vaccines market include:
- Bayer AG (Germany)
- Boehringer Ingelheim GmbH (Germany)
- Ceva Santé Animale (France)
- Eli Lilly and Company (U.S)
- Hester biosciences (India)
- Merck & Co., Inc. (U.S)
- Vétoquinol S.A. (France)
- Virbac S.A. (France)
- Zoetis Inc. (U.S)
KEY FINDINGS OF THE REPORT:
- Veterinary Vaccines market expanding at 5.6% CAGR over 2017 to 2023 to reach market value of US$ 8,368 Mn by 2023 owing to increased adoption pet animals and rising meat consumption
- Based on product type livestock vaccines accounted for larger market revenue share in 2016 and projected gain market revenue share over the forecast period
- Live attenuated vaccines segment garnered larger revenue share in global 2016 and projected to remain dominant over the forecast period
- Players focusing on launching products to retain market position in global veterinary vaccines market
- The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
By Product Type
- Live Stock Vaccines
- Bovine Vaccines
- Poultry Vaccines
- Small Ruminants Vaccines
- Companion Animal Vaccine
- Canine Vaccines
- Feline Vaccines
- Porcine Vaccines
- Equine Vaccines
- Others
- Live Stock Diseases
- Foot and Mouth Diseases
- Brucellosis
- Infectious Bronchitis
- Marek’s Disease
- Newcastle Disease
- Others
- Companion Animal Diseases
- Canine Distemper
- Canine Parvovirus
- Feline Rabies
- Others
- Equine Diseases
- Porcine Diseases
- Aquaculture Diseases
- Live Attenuated Vaccines
- Inactivated Vaccines
- Recombinant vaccines
- Toxoid vaccines
- Conjugate Vaccines
- DNA Vaccines
- Subunit Vaccines
- Veterinary Pharmacies
- Veterinary Hospitals
- Veterinary Clinics
- E-Commerce
- North America
- U.S
- Canada
- Europe
- Germany
- France
- U.K
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Venezuela
- Rest of Latin America
- Middle East and Africa (MEA)
- Gulf Cooperation Council (GCC) Countries
- Israel
- South Africa
1. RESEARCH METHODOLOGY
1.1. Secondary and Primary research
1.1.1. Secondary Sources
1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms
2. SCOPE OF STUDY
2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study
3. EXECUTIVE SUMMARY
4. GLOBAL VETERINARY VACCINES MARKET DYNAMIC FACTORS
4.1. Drivers
4.1.1. Economic Drivers
4.1.2. Demand Side Drivers
4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends
5. UNIQUE FEATURES OF THE REPORT
5.1. Competition analysis
5.1.1. Dash board of top players
5.1.2. Financial Analysis
5.1.3. Product & Services
5.1.4. Key Developments
5.1.5. Major Strategies
5.1.6. SWOT Analysis
5.2. Technological advancements in veterinary vaccines market
5.3. Recent investments in the industry
5.4. Regulatory landscape
5.4.1. U.S.
5.4.2. Europe
5.5. PESTLE analysis
5.6. Porter’s analysis
6. GLOBAL VETERINARY VACCINES MARKET, BY PRODUCT, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Live Stock Vaccines
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.1.3. Bovine Vaccine
6.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.1.4. Poultry Vaccines
6.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.1.5. Small Ruminants Vaccine
6.1.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. Companion Animal Vaccine
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2.3. Canine Vaccines
6.2.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2.4. Feline Vaccines
6.2.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.3. Porcine Vaccines
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.4. Equine Vaccines
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.5. Others
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7. GLOBAL VETERINARY VACCINES MARKET FORECAST, BY DISEASE, 2012 - 2016 AND FORECAST, 2017 – 2023
7.1. Live Stock Diseases
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.1.3. Foot and Mouth Disease
7.1.4. Brucellosis
7.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.1.5. Infectious Bronchitis
7.1.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.1.6. Marek’s Disease
7.1.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.1.7. Newcastle Disease
7.1.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.1.8. Others
7.1.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Companion Animal Diseases
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2.3. Canine Distemper
7.2.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2.4. Canine Parvovirus
7.2.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2.5. Feline Rabies
7.2.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2.6. Others
7.2.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.3. Equine Diseases
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.4. Porcine Diseases
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.5. Aquaculture Diseases
7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8. GLOBAL VETERINARY VACCINES MARKET FORECAST, BY VACCINE TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023
8.1. Live Attenuated Vaccines
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Inactivated Vaccines
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.3. Recombinant Vaccines
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.4. Toxoid Vaccines
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.5. Conjugate Vaccines
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.6. DNA Vaccines
8.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.7. Subunit Vaccines
8.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9. GLOBAL VETERINARY VACCINES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023
9.1. Veterinary Hospitals
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.2. Veterinary Clinics
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.3. Others
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
10. VETERINARY VACCINES MARKET FORECAST, BY REGION ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. North America Veterinary Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.1.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.1.1. Live Stock Vaccines
10.1.1.1.1. Bovine Vaccine
10.1.1.1.2. Poultry Vaccines
10.1.1.1.3. Small Ruminants Vaccine
10.1.1.2. Companion Animal Vaccine
10.1.1.2.1. Canine Vaccines
10.1.1.2.2. Feline Vaccines
10.1.1.3. Porcine Vaccines
10.1.1.4. Equine Vaccines
10.1.1.5. Others
10.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.2.1. Live Stock Diseases
10.1.2.1.1. Foot and Mouth Disease
10.1.2.1.2. Brucellosis
10.1.2.1.3. Infectious Bronchitis
10.1.2.1.4. Marek’s Disease
10.1.2.1.5. Newcastle Disease
10.1.2.1.6. Others
10.1.2.2. Companion Animal Diseases
10.1.2.2.1. Canine Distemper
10.1.2.2.2. Canine Parvovirus
10.1.2.2.3. Feline Rabies
10.1.2.2.4. Others
10.1.2.3. Equine Diseases
10.1.2.4. Porcine Diseases
10.1.2.5. Aquaculture Diseases
10.1.2.6. Others
10.1.3. Vaccine Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.3.1. Live Attenuated Vaccines
10.1.3.2. Inactivated Vaccines
10.1.3.3. Recombinant Vaccines
10.1.3.4. Toxoid vaccines
10.1.3.5. Conjugate Vaccines
10.1.3.6. DNA Vaccines
10.1.3.7. Subunit Vaccines
10.1.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.4.1. Veterinary Pharmacies
10.1.4.2. Veterinary Hospitals
10.1.4.3. Veterinary Clinics
10.1.4.4. E-Commerce
10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.5.1. U.S.
10.1.5.2. Canada
10.2. Europe Veterinary Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.2.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.1.1. Live Stock Vaccines
10.2.1.1.1. Bovine Vaccine
10.2.1.1.2. Poultry Vaccines
10.2.1.1.3. Small Ruminants Vaccine
10.2.1.2. Companion Animal Vaccine
10.2.1.2.1. Canine Vaccines
10.2.1.2.2. Feline Vaccines
10.2.1.3. Porcine Vaccines
10.2.1.4. Equine Vaccines
10.2.1.5. Others
10.2.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.2.1. Live Stock Diseases
10.2.2.1.1. Foot and Mouth Disease
10.2.2.1.2. Brucellosis
10.2.2.1.3. Infectious Bronchitis
10.2.2.1.4. Marek’s Disease
10.2.2.1.5. Newcastle Disease
10.2.2.1.6. Others
10.2.2.2. Companion Animal Diseases
10.2.2.2.1. Canine Distemper
10.2.2.2.2. Canine Parvovirus
10.2.2.2.3. Feline Rabies
10.2.2.2.4. Others
10.2.2.3. Equine Diseases
10.2.2.4. Porcine Diseases
10.2.2.5. Aquaculture Diseases
10.2.2.6. Others
10.2.3. Vaccine Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.3.1. Live Attenuated Vaccines
10.2.3.2. Inactivated Vaccines
10.2.3.3. Recombinant Vaccines
10.2.3.4. Toxoid vaccines
10.2.3.5. Conjugate Vaccines
10.2.3.6. DNA Vaccines
10.2.3.7. Subunit Vaccines
10.2.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.4.1. Veterinary Pharmacies
10.2.4.2. Veterinary Hospitals
10.2.4.3. Veterinary Clinics
10.2.4.4. E-Commerce
10.2.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.5.1. Germany
10.2.5.2. UK
10.2.5.3. France
10.2.5.4. Spain
10.2.5.5. Italy
10.2.5.6. Russia
10.2.5.7. Poland 10.2.5.8. Rest of Europe
10.3. Asia-Pacific Veterinary Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.3.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.1.1. Live Stock Vaccines
10.3.1.1.1. Bovine Vaccine
10.3.1.1.2. Poultry Vaccines
10.3.1.1.3. Small Ruminants Vaccine
10.3.1.2. Companion Animal Vaccine
10.3.1.2.1. Canine Vaccines
10.3.1.2.2. Feline Vaccines
10.3.1.3. Porcine Vaccines
10.3.1.4. Equine Vaccines
10.3.1.5. Others
10.3.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.2.1. Live Stock Diseases
10.3.2.1.1. Foot and Mouth Disease
10.3.2.1.2. Brucellosis
10.3.2.1.3. Infectious Bronchitis
10.3.2.1.4. Marek’s Disease
10.3.2.1.5. Newcastle Disease
10.3.2.1.6. Others
10.3.2.2. Companion Animal Diseases
10.3.2.2.1. Canine Distemper
10.3.2.2.2. Canine Parvovirus
10.3.2.2.3. Feline Rabies
10.3.2.2.4. Others
10.3.2.3. Equine Diseases
10.3.2.4. Porcine Diseases
10.3.2.5. Aquaculture Diseases
10.3.2.6. Others
10.3.3. Vaccine Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.3.1. Live Attenuated Vaccines
10.3.3.2. Inactivated Vaccines
10.3.3.3. Recombinant Vaccines
10.3.3.4. Toxoid vaccines
10.3.3.5. Conjugate Vaccines
10.3.3.6. DNA Vaccines
10.3.3.7. Subunit Vaccines
10.3.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.4.1. Veterinary Pharmacies
10.3.4.2. Veterinary Hospitals
10.3.4.3. Veterinary Clinics
10.3.4.4. E-Commerce
10.3.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.5.1. Japan
10.3.5.2. China
10.3.5.3. India
10.3.5.4. ASEAN
10.3.5.5. Australia & New Zealand 10.3.5.6. Rest of Asia-Pacific
10.4. Latin America Veterinary Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.4.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.1.1. Live Stock Vaccines
10.4.1.1.1. Bovine Vaccine
10.4.1.1.2. Poultry Vaccines
10.4.1.1.3. Small Ruminants Vaccine
10.4.1.2. Companion Animal Vaccine
10.4.1.2.1. Canine Vaccines
10.4.1.2.2. Feline Vaccines
10.4.1.3. Porcine Vaccines
10.4.1.4. Equine Vaccines
10.4.1.5. Others
10.4.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.2.1. Live Stock Diseases
10.4.2.1.1. Foot and Mouth Disease
10.4.2.1.2. Brucellosis
10.4.2.1.3. Infectious Bronchitis
10.4.2.1.4. Marek’s Disease
10.4.2.1.5. Newcastle Disease
10.4.2.1.6. Others
10.4.2.2. Companion Animal Diseases
10.4.2.2.1. Canine Distemper
10.4.2.2.2. Canine Parvovirus
10.4.2.2.3. Feline Rabies
10.4.2.2.4. Others
10.4.2.3. Equine Diseases
10.4.2.4. Porcine Diseases
10.4.2.5. Aquaculture Diseases
10.4.2.6. Others
10.4.3. Vaccine Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.3.1. Live Attenuated Vaccines
10.4.3.2. Inactivated Vaccines
10.4.3.3. Recombinant Vaccines
10.4.3.4. Toxoid vaccines
10.4.3.5. Conjugate Vaccines
10.4.3.6. DNA Vaccines
10.4.3.7. Subunit Vaccines
10.4.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.4.1. Veterinary Pharmacies
10.4.4.2. Veterinary Hospitals
10.4.4.3. Veterinary Clinics
10.4.4.4. E-Commerce
10.4.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.5.1. Brazil
10.4.5.2. Mexico
10.4.5.3. Argentina
10.4.5.4. Venezuela
10.4.5.5. Rest of Latin America
10.5. Middle East & Africa (MEA) Veterinary Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.5.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.1.1. Live Stock Vaccines
10.5.1.1.1. Bovine Vaccine
10.5.1.1.2. Poultry Vaccines
10.5.1.1.3. Small Ruminants Vaccine
10.5.1.2. Companion Animal Vaccine
10.5.1.2.1. Canine Vaccines
10.5.1.2.2. Feline Vaccines
10.5.1.3. Porcine Vaccines
10.5.1.4. Equine Vaccines
10.5.1.5. Others
10.5.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.2.1. Live Stock Diseases
10.5.2.1.1. Foot and Mouth Disease
10.5.2.1.2. Brucellosis
10.5.2.1.3. Infectious Bronchitis
10.5.2.1.4. Marek’s Disease
10.5.2.1.5. Newcastle Disease
10.5.2.1.6. Others
10.5.2.2. Companion Animal Diseases
10.5.2.2.1. Canine Distemper
10.5.2.2.2. Canine Parvovirus
10.5.2.2.3. Feline Rabies
10.5.2.2.4. Others
10.5.2.3. Equine Diseases
10.5.2.4. Porcine Diseases
10.5.2.5. Aquaculture Diseases
10.5.2.6. Others
10.5.3. Vaccine Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.3.1. Live Attenuated Vaccines
10.5.3.2. Inactivated Vaccines
10.5.3.3. Recombinant Vaccines
10.5.3.4. Toxoid vaccines
10.5.3.5. Conjugate Vaccines
10.5.3.6. DNA Vaccines
10.5.3.7. Subunit Vaccines
10.5.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.4.1. Veterinary Pharmacies
10.5.4.2. Veterinary Hospitals
10.5.4.3. Veterinary Clinics
10.5.4.4. E-Commerce
10.5.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.5.1. Gulf Cooperation Council (GCC) Countries
10.5.5.2. Israel
10.5.5.3. South Africa
10.5.5.4. Rest of MEA
11. COMPETITION LANDSCAPE
11.1. Strategic Dashboard of Top Market Players
11.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
11.2.1. Bayer AG (Germany)
11.2.2. Boehringer Ingelheim GmbH (Germany)
11.2.3. Ceva Santé Animale (France)
11.2.4. Eli Lilly and Company (U.S)
11.2.5. Hester biosciences (India)
11.2.6. Merck & Co., Inc. (U.S)
11.2.7. Vétoquinol S.A. (France)
11.2.8. Virbac S.A. (France)
11.2.9. Zoetis Inc. (U.S)
1.1. Secondary and Primary research
1.1.1. Secondary Sources
1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms
2. SCOPE OF STUDY
2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study
3. EXECUTIVE SUMMARY
4. GLOBAL VETERINARY VACCINES MARKET DYNAMIC FACTORS
4.1. Drivers
4.1.1. Economic Drivers
4.1.2. Demand Side Drivers
4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends
5. UNIQUE FEATURES OF THE REPORT
5.1. Competition analysis
5.1.1. Dash board of top players
5.1.2. Financial Analysis
5.1.3. Product & Services
5.1.4. Key Developments
5.1.5. Major Strategies
5.1.6. SWOT Analysis
5.2. Technological advancements in veterinary vaccines market
5.3. Recent investments in the industry
5.4. Regulatory landscape
5.4.1. U.S.
5.4.2. Europe
5.5. PESTLE analysis
5.6. Porter’s analysis
6. GLOBAL VETERINARY VACCINES MARKET, BY PRODUCT, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Live Stock Vaccines
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.1.3. Bovine Vaccine
6.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.1.4. Poultry Vaccines
6.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.1.5. Small Ruminants Vaccine
6.1.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. Companion Animal Vaccine
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2.3. Canine Vaccines
6.2.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2.4. Feline Vaccines
6.2.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.3. Porcine Vaccines
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.4. Equine Vaccines
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.5. Others
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7. GLOBAL VETERINARY VACCINES MARKET FORECAST, BY DISEASE, 2012 - 2016 AND FORECAST, 2017 – 2023
7.1. Live Stock Diseases
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.1.3. Foot and Mouth Disease
7.1.4. Brucellosis
7.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.1.5. Infectious Bronchitis
7.1.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.1.6. Marek’s Disease
7.1.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.1.7. Newcastle Disease
7.1.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.1.8. Others
7.1.8.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.1.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Companion Animal Diseases
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2.3. Canine Distemper
7.2.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2.4. Canine Parvovirus
7.2.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2.5. Feline Rabies
7.2.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2.6. Others
7.2.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.3. Equine Diseases
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.4. Porcine Diseases
7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.5. Aquaculture Diseases
7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8. GLOBAL VETERINARY VACCINES MARKET FORECAST, BY VACCINE TYPE, 2012 - 2016 AND FORECAST, 2017 – 2023
8.1. Live Attenuated Vaccines
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.2. Inactivated Vaccines
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.3. Recombinant Vaccines
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.4. Toxoid Vaccines
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.5. Conjugate Vaccines
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.6. DNA Vaccines
8.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
8.7. Subunit Vaccines
8.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
8.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9. GLOBAL VETERINARY VACCINES MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023
9.1. Veterinary Hospitals
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.2. Veterinary Clinics
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
9.3. Others
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
10. VETERINARY VACCINES MARKET FORECAST, BY REGION ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. North America Veterinary Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.1.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.1.1. Live Stock Vaccines
10.1.1.1.1. Bovine Vaccine
10.1.1.1.2. Poultry Vaccines
10.1.1.1.3. Small Ruminants Vaccine
10.1.1.2. Companion Animal Vaccine
10.1.1.2.1. Canine Vaccines
10.1.1.2.2. Feline Vaccines
10.1.1.3. Porcine Vaccines
10.1.1.4. Equine Vaccines
10.1.1.5. Others
10.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.2.1. Live Stock Diseases
10.1.2.1.1. Foot and Mouth Disease
10.1.2.1.2. Brucellosis
10.1.2.1.3. Infectious Bronchitis
10.1.2.1.4. Marek’s Disease
10.1.2.1.5. Newcastle Disease
10.1.2.1.6. Others
10.1.2.2. Companion Animal Diseases
10.1.2.2.1. Canine Distemper
10.1.2.2.2. Canine Parvovirus
10.1.2.2.3. Feline Rabies
10.1.2.2.4. Others
10.1.2.3. Equine Diseases
10.1.2.4. Porcine Diseases
10.1.2.5. Aquaculture Diseases
10.1.2.6. Others
10.1.3. Vaccine Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.3.1. Live Attenuated Vaccines
10.1.3.2. Inactivated Vaccines
10.1.3.3. Recombinant Vaccines
10.1.3.4. Toxoid vaccines
10.1.3.5. Conjugate Vaccines
10.1.3.6. DNA Vaccines
10.1.3.7. Subunit Vaccines
10.1.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.4.1. Veterinary Pharmacies
10.1.4.2. Veterinary Hospitals
10.1.4.3. Veterinary Clinics
10.1.4.4. E-Commerce
10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.1.5.1. U.S.
10.1.5.2. Canada
10.2. Europe Veterinary Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.2.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.1.1. Live Stock Vaccines
10.2.1.1.1. Bovine Vaccine
10.2.1.1.2. Poultry Vaccines
10.2.1.1.3. Small Ruminants Vaccine
10.2.1.2. Companion Animal Vaccine
10.2.1.2.1. Canine Vaccines
10.2.1.2.2. Feline Vaccines
10.2.1.3. Porcine Vaccines
10.2.1.4. Equine Vaccines
10.2.1.5. Others
10.2.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.2.1. Live Stock Diseases
10.2.2.1.1. Foot and Mouth Disease
10.2.2.1.2. Brucellosis
10.2.2.1.3. Infectious Bronchitis
10.2.2.1.4. Marek’s Disease
10.2.2.1.5. Newcastle Disease
10.2.2.1.6. Others
10.2.2.2. Companion Animal Diseases
10.2.2.2.1. Canine Distemper
10.2.2.2.2. Canine Parvovirus
10.2.2.2.3. Feline Rabies
10.2.2.2.4. Others
10.2.2.3. Equine Diseases
10.2.2.4. Porcine Diseases
10.2.2.5. Aquaculture Diseases
10.2.2.6. Others
10.2.3. Vaccine Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.3.1. Live Attenuated Vaccines
10.2.3.2. Inactivated Vaccines
10.2.3.3. Recombinant Vaccines
10.2.3.4. Toxoid vaccines
10.2.3.5. Conjugate Vaccines
10.2.3.6. DNA Vaccines
10.2.3.7. Subunit Vaccines
10.2.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.4.1. Veterinary Pharmacies
10.2.4.2. Veterinary Hospitals
10.2.4.3. Veterinary Clinics
10.2.4.4. E-Commerce
10.2.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.2.5.1. Germany
10.2.5.2. UK
10.2.5.3. France
10.2.5.4. Spain
10.2.5.5. Italy
10.2.5.6. Russia
10.2.5.7. Poland 10.2.5.8. Rest of Europe
10.3. Asia-Pacific Veterinary Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.3.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.1.1. Live Stock Vaccines
10.3.1.1.1. Bovine Vaccine
10.3.1.1.2. Poultry Vaccines
10.3.1.1.3. Small Ruminants Vaccine
10.3.1.2. Companion Animal Vaccine
10.3.1.2.1. Canine Vaccines
10.3.1.2.2. Feline Vaccines
10.3.1.3. Porcine Vaccines
10.3.1.4. Equine Vaccines
10.3.1.5. Others
10.3.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.2.1. Live Stock Diseases
10.3.2.1.1. Foot and Mouth Disease
10.3.2.1.2. Brucellosis
10.3.2.1.3. Infectious Bronchitis
10.3.2.1.4. Marek’s Disease
10.3.2.1.5. Newcastle Disease
10.3.2.1.6. Others
10.3.2.2. Companion Animal Diseases
10.3.2.2.1. Canine Distemper
10.3.2.2.2. Canine Parvovirus
10.3.2.2.3. Feline Rabies
10.3.2.2.4. Others
10.3.2.3. Equine Diseases
10.3.2.4. Porcine Diseases
10.3.2.5. Aquaculture Diseases
10.3.2.6. Others
10.3.3. Vaccine Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.3.1. Live Attenuated Vaccines
10.3.3.2. Inactivated Vaccines
10.3.3.3. Recombinant Vaccines
10.3.3.4. Toxoid vaccines
10.3.3.5. Conjugate Vaccines
10.3.3.6. DNA Vaccines
10.3.3.7. Subunit Vaccines
10.3.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.4.1. Veterinary Pharmacies
10.3.4.2. Veterinary Hospitals
10.3.4.3. Veterinary Clinics
10.3.4.4. E-Commerce
10.3.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.3.5.1. Japan
10.3.5.2. China
10.3.5.3. India
10.3.5.4. ASEAN
10.3.5.5. Australia & New Zealand 10.3.5.6. Rest of Asia-Pacific
10.4. Latin America Veterinary Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.4.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.1.1. Live Stock Vaccines
10.4.1.1.1. Bovine Vaccine
10.4.1.1.2. Poultry Vaccines
10.4.1.1.3. Small Ruminants Vaccine
10.4.1.2. Companion Animal Vaccine
10.4.1.2.1. Canine Vaccines
10.4.1.2.2. Feline Vaccines
10.4.1.3. Porcine Vaccines
10.4.1.4. Equine Vaccines
10.4.1.5. Others
10.4.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.2.1. Live Stock Diseases
10.4.2.1.1. Foot and Mouth Disease
10.4.2.1.2. Brucellosis
10.4.2.1.3. Infectious Bronchitis
10.4.2.1.4. Marek’s Disease
10.4.2.1.5. Newcastle Disease
10.4.2.1.6. Others
10.4.2.2. Companion Animal Diseases
10.4.2.2.1. Canine Distemper
10.4.2.2.2. Canine Parvovirus
10.4.2.2.3. Feline Rabies
10.4.2.2.4. Others
10.4.2.3. Equine Diseases
10.4.2.4. Porcine Diseases
10.4.2.5. Aquaculture Diseases
10.4.2.6. Others
10.4.3. Vaccine Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.3.1. Live Attenuated Vaccines
10.4.3.2. Inactivated Vaccines
10.4.3.3. Recombinant Vaccines
10.4.3.4. Toxoid vaccines
10.4.3.5. Conjugate Vaccines
10.4.3.6. DNA Vaccines
10.4.3.7. Subunit Vaccines
10.4.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.4.1. Veterinary Pharmacies
10.4.4.2. Veterinary Hospitals
10.4.4.3. Veterinary Clinics
10.4.4.4. E-Commerce
10.4.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.4.5.1. Brazil
10.4.5.2. Mexico
10.4.5.3. Argentina
10.4.5.4. Venezuela
10.4.5.5. Rest of Latin America
10.5. Middle East & Africa (MEA) Veterinary Vaccines Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.5.1. Product Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.1.1. Live Stock Vaccines
10.5.1.1.1. Bovine Vaccine
10.5.1.1.2. Poultry Vaccines
10.5.1.1.3. Small Ruminants Vaccine
10.5.1.2. Companion Animal Vaccine
10.5.1.2.1. Canine Vaccines
10.5.1.2.2. Feline Vaccines
10.5.1.3. Porcine Vaccines
10.5.1.4. Equine Vaccines
10.5.1.5. Others
10.5.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.2.1. Live Stock Diseases
10.5.2.1.1. Foot and Mouth Disease
10.5.2.1.2. Brucellosis
10.5.2.1.3. Infectious Bronchitis
10.5.2.1.4. Marek’s Disease
10.5.2.1.5. Newcastle Disease
10.5.2.1.6. Others
10.5.2.2. Companion Animal Diseases
10.5.2.2.1. Canine Distemper
10.5.2.2.2. Canine Parvovirus
10.5.2.2.3. Feline Rabies
10.5.2.2.4. Others
10.5.2.3. Equine Diseases
10.5.2.4. Porcine Diseases
10.5.2.5. Aquaculture Diseases
10.5.2.6. Others
10.5.3. Vaccine Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.3.1. Live Attenuated Vaccines
10.5.3.2. Inactivated Vaccines
10.5.3.3. Recombinant Vaccines
10.5.3.4. Toxoid vaccines
10.5.3.5. Conjugate Vaccines
10.5.3.6. DNA Vaccines
10.5.3.7. Subunit Vaccines
10.5.4. Distribution Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.4.1. Veterinary Pharmacies
10.5.4.2. Veterinary Hospitals
10.5.4.3. Veterinary Clinics
10.5.4.4. E-Commerce
10.5.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
10.5.5.1. Gulf Cooperation Council (GCC) Countries
10.5.5.2. Israel
10.5.5.3. South Africa
10.5.5.4. Rest of MEA
11. COMPETITION LANDSCAPE
11.1. Strategic Dashboard of Top Market Players
11.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
11.2.1. Bayer AG (Germany)
11.2.2. Boehringer Ingelheim GmbH (Germany)
11.2.3. Ceva Santé Animale (France)
11.2.4. Eli Lilly and Company (U.S)
11.2.5. Hester biosciences (India)
11.2.6. Merck & Co., Inc. (U.S)
11.2.7. Vétoquinol S.A. (France)
11.2.8. Virbac S.A. (France)
11.2.9. Zoetis Inc. (U.S)
